1. Schermerhorn headshot

Comparing TCAR to the Traditional Approach for the Treatment of Carotid Artery Stenosis: An Interview With Dr Marc Schermerhorn

In this interview, Dr. Schermerhorn discusses the results of the TCAR (Trans-Carotid Artery Revascularization) trial, which compared TCAR with CEA in patients with carotid stenosis. | Read More

Geniculate Artery Embolization Offers Pain Relief From Osteoarthritis

Rachel Piechowiak, DO, discusses the implications of a US clinical trial which investigated the use of geniculate artery embolization for decreasing inflammation and pain in osteoarthritis-related knee pain by blocking abnormal blood vessels in the… | Read More

  1. Comerota headshot

The ATTRACT Trial: Understanding the Results

The recent publication of the landmark ATTRACT trial has offere | Read More

A Novel Device to Prevent Neointimal Hyperplasia Restenosis: The DANCE and LIMBO Trials

VDM spoke with George Adams, MD, MHS, at the 43rd Annual VEITH Symposium regarding the ongoing DANCE and LIMBO trials. | Read More

Preliminary Results From the DRASTICO Trial: A Discussion With Francesco Liistro, MD

An interview with the principal investigator of the ongoing DRASTICO trial, which is comparing drug-eluting stent vs drug-eluting balloon in complex patients. | Read More

Bioresorbable Scaffolds and the Future for the “Leave Nothing Behind” Movement: A Discussion With Johannes Lammer, MD

Johannes Lammer, MD, is professor of radiology and interventional radiology at the Medical University of Vienna in Vienna, Austria. Dr. Lammer is principal investigator for the ESPRIT I trial, which evaluated the safety and performance of the ESPRIT… | Read More

Gary Ansel, MD, Describes New Subanalyses From Zilver PTX

At VEITH Symposium, Dr. Ansel shared new findings from subanalyses as well as 5-year results that show widening benefits from the drug-eluting stent. | Read More

Turning to the Use of GP IIb/IIIa Inhibitors, an Emerging Pharmacologic Approach for CLI: An Interview With Craig Walker, MD

The FDA recently approved a new, more concentrated format of the high-dose bolus of the GP IIb/IIIa agent tirofiban (premixed, ready to use, at 250 mcg/mL in a 15 mL vial). Craig Walker, MD, answers questions about the use of GP IIb/IIIa agents in… | Read More

IN.PACT Global 1-Year Results: An Interview With Michael R. Jaff, DO

The 1-year results from IN.PACT Global confirm safety and effectiveness of the In.Pact Admiral DCB in femoropopliteal lesions. Michael R. Jaff, DO, answers questions about the results and their implications for peripheral vascular therapy. | Read More